MEXATE Drug Patent Profile
✉ Email this page to a colleague
When do Mexate patents expire, and what generic alternatives are available?
Mexate is a drug marketed by Bristol, Bristol Myers, and Bristol Myers Squibb. and is included in three NDAs.
The generic ingredient in MEXATE is methotrexate sodium. There are twenty drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the methotrexate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mexate
A generic version of MEXATE was approved as methotrexate sodium by HIKMA on September 16th, 1986.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MEXATE?
- What are the global sales for MEXATE?
- What is Average Wholesale Price for MEXATE?
Summary for MEXATE
US Patents: | 0 |
Applicants: | 3 |
NDAs: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 137 |
Clinical Trials: | 131 |
Patent Applications: | 4,355 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MEXATE at DailyMed |
![MEXATE drug patent expirations Drug patent expirations by year for MEXATE](/p/graph/s/t/MEXATE-patent-expirations.png)
Recent Clinical Trials for MEXATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
City of Hope Medical Center | Phase 2 |
Children's Oncology Group | Phase 2/Phase 3 |
City of Hope Medical Center | Phase 1 |
US Patents and Regulatory Information for MEXATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol | MEXATE | methotrexate sodium | INJECTABLE;INJECTION | 086358-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Bristol | MEXATE | methotrexate sodium | INJECTABLE;INJECTION | 086358-004 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Bristol | MEXATE | methotrexate sodium | INJECTABLE;INJECTION | 086358-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Bristol | MEXATE | methotrexate sodium | INJECTABLE;INJECTION | 086358-003 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Bristol Myers Squibb | MEXATE-AQ PRESERVED | methotrexate sodium | INJECTABLE;INJECTION | 089887-001 | Apr 14, 1989 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Bristol Myers | MEXATE-AQ | methotrexate sodium | INJECTABLE;INJECTION | 088760-001 | Feb 14, 1985 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |